References to Primary Literature
- Pavia, MR Davis, RE Schwartz, RD Cognition Enhancers. Ann. Repts. Med. Chem. 1990 25 21–29 A recent review on cognition enhancers.
- Miller, SW Mahloney, JM Jann, MW Therapeutic Frontiers in Alzheimer's Disease. Pharmacother. 1992 12 217–231 A review on drugs which are currently in the clinical trials for Alzheimer's Disease.
- Kosik, KS Alzheimer's Disease: A Cell Biological Perspective. Science 1992 256 780–783.
- Selkoe, DJ Amyloid Protein and Alzheimer's Disease. Sci. Amer. 1991 265 68–78.
- Hardy, JA Higgins, GA Alzheimer's Disease: The Amyloid Cascade Hypothesis. Science 1992 256 184–185.
- Koliatsos, VE Clatterbuck, RE Gouras, GK Price, DL Biological Effects of Nerve Growth Factor on Lesioned Basal Forebrain Neurons. Ann. N.Y. Acad. Sci. 1991 640 102–9.
- Showell, GA Baker, R Davis, J Hargreaves, R Freedman, SB Hoogsteen, K Patel, S Snow, RJ Synthesis and in vitro biological profile of all four isomers of the potent muscarinic agonist 3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-azabicyclo[2.2.1]heptane. J. Med Chem. 1992 35 911–916 The first paper describes the biological activity of all four isomers of the Merck's superagonist.
- Saunders, J Freedman, SB The design of full agonists for cortical muscarinic receptors. Trends Pharmacol. Sci.: Subtypes of Muscarinic Receptors IV 1989 70–75.
- Shapiro, G Floersheim, P Boelsterli, J Amstutz, R Bolliger, G Gammenthaler, H Gmelin, G Supavilai, P Walkinshaw, M Muscarinic activity of the thiolactone, lactam, lactol, and thiolactol analogues of pilocarpine and a hypothetical model for the binding of agonists to the m1 receptor. J. Med. Chem. 1992 35 15–27.
- Street, LJ Baker, R Book, T Reeve, AJ Saunders, J Willson, T Marwood, RS Patel, S Freedman, SB Synthesis and Muscarinic Activity of Quinuclidinyl- and (1-azanorbornyl)pyrazine derivatives. J. Med. Chem. 1992 35 295–305.
- Sauerberg, P Olesen, PH Nielsen, S Treppendahl, S Sheardown, MJ Honore, T Mitch, CH Ward, JS Pike, AJ Bymaster, FP Sawyer, BD Shannon, HE Novel Functional M1 Selective Muscarinic Agonists. J. Med. Chem. 1992 35 2274–2283 Novel functional M1 selective muscarinic agonists with floppy side chain and with potent affinity to displace [3H]-Pz and high efficay (IC50 = 0.004–0.008 nM) in M1 functional assay.
- Wadsworth, HJ Jenkins, SM Orlek, BS Cassidy, MSG Brown, F Riley, GJ Graves, D Hawkins, J Naylor, CB Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J. Med. Chem. 1992 35 1280.
- Freeman, SB Patel, S Harley, EA Iversen, LL Baker, R Showell, GA Saunders, J McKnight, A Newberry, N Scholey, K Hargreaves, R L-687,306: A Functionally Selective and Potent Muscarinic M1 Receptor Agonist. Europ. J. Pharmacol. 1992 215 135–136.
- Wu, ESC Griffith, RG Loch, JT III Kover, A Blosser, JC Machulskis, A McCreedy, SA Synthesis and biological studies of centrally acting muscarinic agents: Spiromuscarones Abstracts of Papers, 200th National Meeting of the Amer. Chem. Soc. Atlanta, GA 1991 MEDI 106.
- Loch, JT III Wu, ESC Griffith, RG Kover, A Blosser, JC Machulskis, A McCreedy, SA Spiromuscarones and related analogues: Synthesis and muscarinic activity Abstracts of Papers, 23rd Medicinal Chemistry Symposium of the Amer. Chem. Soc. Buffalo, NY 1992 ABSTRACT 8.
- Nordvall, G Sundquist, S Glas, G Gogoll, A Nilvebrant, L Hacksell, U Analogues of the muscarinic agent 2'-methylspirotl-azabicyclo[2.2.2]octane-3',4'-[1,3]dioxolane]: Synthesis and pharmacology. J. Med. Chem. 1992 35 1541–1550.
- Freeman, SB Harley, EA Iversen, LL Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: The NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors. Br. J. Pharmacol. 1988 93 437–445.
- Levin, JL Fanshawe, WJ Epstein, JW Beer, B Bartus, RT Dean, RL III Synthesis and Activity in Cognition-related Tests of Novel 2-Benzoylamino-4-oxoquinazolines. Bioorg. Med. Chem. Lett. 1992 2 349–352.
- Hargreaves, RJ McKnight, AT Newberry, N Scholey, K Tang, J Street, L Baker, R Hutson, P Semark, J Harley, EA Patel, S Freeman, SB L-689,660: A functionally selective agonist at M1 and M3 muscarinic receptors. Brit. J. Pharmacol. 1991 104 456P.
- Chen, YL Nielsen, J Hedberg, K Dunaiskis, A Jones, S Russo, L Johnson, J Ives, J Liston, D Synthesis, resolution, and structure-activity relationships of potent acetylcholinesterase inhibitors: 8-carbaphysostigmine analogues. J. Med. Chem. 1992 35 1429.
- Cardozo, MG Kawai, T Imura, Y Sugimoto, H Yamanishi, Y Hopfinger, AJ QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J. Med. Chem. 1992 35 584–589.
References to Patent literature
- Novo Nordisk AS WO 9203430, WO9203431.
- Novo Nordisk AS WO 9203433.
- Merck Sharp & Dohme Ltd EP -473442-A.
- Fisons Corporation US 5075317.
- Fisons Corporation US 5073560.
- Fisons Corporation WO 9201690.
- Yamanouchi Pharm KK JP 4018092.
- Fisons Corporation EP -491562-A.
- Beecham Group plc WO 9204323.
- Beecham Group plc WO 9206959.
- Beecham Group plc WO 9203435.
- Gyógyszerkutató Intéazet KV WO 9207854.
- Warner-Lambert Company US 5068237.
- American Cyanamid Co US 5089518.
- American Home Products Corp US 5093333.
- Sanofi SA EP -469992-A.
- Sankyo Company Limited EP -456–519-A.
- Nippon Shinyaku Co Ltd WO 9204333.
- American Cyanamid Co US 5084457.
- National Research Development Corp GB 2249093-A.
- Marion Merrell Dow Inc EP -486734-A.
- Pfizer Limited WO 9204346.
- Pfizer Limited WO 9205172.
- Merck & Co Inc EP -479524-A.
- Merck Sharp & Dohme Ltd EP -416754-A.
- Merck Sharp & Dohme Ltd EP -470668-A.
- Mediolanum Farmaceutici SpA EP -486958-A.
- Hoechst-Roussel Pharmaceuticals inc WO 9200072.
- Hoechst-Roussel Pharmaceuticals Inc EP -484573-A.
- Hoechst-Roussel Pharmaceuticals Inc US 5100891.
- Pfizer Inc WO 9200961.
- Hoechst-Roussel Pharmaceuticals Inc EP -471296-A.
- Hoechst-Roussel Pharmaceuticals Inc EP -468401-A.
- Hoechst-Roussel Pharmaceuticals Inc EP -471298-A.
- Hoechst-Roussel Pharmaceuticals Inc EP -477903-A.
- SS Pharmaceutical Co EP -481429-A.
- Eisai co ltd EP -468187-A Several highly potent AChE inhibitors with IC50 being < 1 nM were disclosed.
- Takeda Chemical Industries LTD EP -487071-A.
- Hoechst-Roussel Pharmaceuticals Inc US 5106856.
- Hoechst-Roussel Pharmaceuticals Inc EP -489379-A.
- Mayo Foundation for Medical Education and Research US 5104880.
- Sumitomo Phamaceuticals Company EP -476933-A.
- Adir Et Compagnie EP -475844-A.
- Boehringer Ingelheim International GmbH WO 9200297.
- Biorex Kutató-Fejlestö KFT WO 9200737.
- Lüdke, H-W WO 9201455.